Sarepta Therapeutics Q1 2024 Adj EPS $0.73 Beats $(0.07) Estimate, Sales $413.464M Beat $373.283M Estimate
Sarepta Therapeutics Q1 2024 Adj EPS $0.73 Beats $(0.07) Estimate, Sales $413.464M Beat $373.283M Estimate
Sarepta Therapeutics 2024年第一季度調整後每股收益爲0.73美元，超過預期（0.07美元），銷售額爲4.13464億美元，超過3.73283億美元的預期
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $(0.07) by 1142.86 percent. This is a 173.74 percent increase over losses of $(0.99) per share from the same period last year. The company reported quarterly sales of $413.464 million which beat the analyst consensus estimate of $373.283 million by 10.76 percent. This is a 63.10 percent increase over sales of $253.500 million the same period last year.
Sarepta Therapeutics（納斯達克股票代碼：SRPT）公佈的季度收益爲每股0.73美元，比分析師普遍預期的0.07美元（0.07美元）高出1142.86個百分點。與去年同期每股虧損0.99美元（0.99）相比，增長了173.74％。該公司公佈的季度銷售額爲4.13464億美元，比分析師普遍預期的3.73283億美元高出10.76％。這比去年同期的2.535億美元銷售額增長了63.10％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。